Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: Cage Rattler who wrote (604)	10/20/1998 3:42:00 PM
From: Robert C. Petersen	Read Replies (1) \| Respond to of 1255

If they gave reporter old data, perhaps some one on staff is suffering from Alzheimer Syndrome. Still, what kind of a reporter would do a report as wide-spread as this without checking....it is esy enough to do on the computer, even I, a Luddite Lost In Cyber Space, can check all of Cortex press releases in a few minutes...seems like sloppy reporting.....Still confused:::nysebob2

To: Cage Rattler who wrote (604)	10/20/1998 8:33:00 PM
From: DavidCG	Read Replies (1) \| Respond to of 1255

Up to date on what? Phase I/IIa testing on humans measures the safety to humans. The testing on rats was complete and turned out great for CX516. Any further rat testing done right now is probably on CX691 compound (a completely new drug). What did you expect NBC to say.... "Well so far, it works excellent in rats...and by the way, on a small sample of human testing there were no adverse side effects and therefore is safe to administer to humans" ? What would be the point? I will agree that it was quick NBC editing and news piece. Maybe the CEO for Cortex isn't photogenic enough for the cameras -possibly why the Psychologix guy was on instead. Who knows. -DavidCG